ASP Isotopes SEC Filings

ASP Isotopes Inc. entered into an underwriting agreement to sell 17,167,380 shares of common stock at $11.65 per share. The underwriters have a 30‑day option to purchase up to 2,575,106 additional shares at the same price.

Gross proceeds are expected to be approximately $210.3 million before underwriting discounts, commissions, and offering expenses. The offering is expected to close on October 16, 2025, subject to customary closing conditions. The sale is being made under the company’s effective Form S‑3 registration statement with a related prospectus and prospectus supplement. Cantor Fitzgerald & Co. and Lucid Capital Markets, LLC are acting as underwriters.

ASP Isotopes (ASPI) Form 4: Interim CEO and COO reported a sale of 22,500 shares of common stock on 10/14/2025 at a weighted average price of $13.599. The filing states these were “sell to cover” transactions executed under a Rule 10b5‑1 trading plan adopted on June 9, 2025 to cover tax withholding tied to vesting of restricted stock awards.

Trades occurred across multiple executions at prices ranging from $12.31 to $14.46. Following the transactions, the reporting person beneficially owns 1,647,193 shares directly.

ASP Isotopes Inc. (ASPI) launched a preliminary prospectus supplement for a primary underwritten offering of common stock on Nasdaq. Cantor Fitzgerald & Co. and Lucid Capital Markets, LLC are joint bookrunning managers. The underwriters have a 30‑day option to purchase additional shares. Net proceeds are intended for general corporate purposes, including working capital, operating expenses, and capital expenditures, and may also support complementary acquisitions (with no binding commitments).

ASPI’s stock last closed at $13.32 on October 13, 2025. Shares outstanding were 93,406,629 as of October 10, 2025; this is a baseline figure, not the amount being offered. The company reported $67.7 million in cash and cash equivalents as of June 30, 2025, and raised $56.3 million in net proceeds in July 2025. Lock‑ups apply following closing: company 90 days; executive officers 60 days plus 30 days; directors 30 days plus 30 days, subject to stated exceptions.

ASP Isotopes Inc. reported business updates via Form 8-K. The company announced a supply agreement for enriched silicon-28 and the acquisition of a radiopharmacy in the United States. A press release with details is furnished as Exhibit 99.1.

Todd Wider, a director of ASP Isotopes Inc. (ASPI), executed equity transactions on 09/14/2025 and 09/15/2025. He acquired 96,000 shares through exercise of stock options with a conversion/exercise price of $2, and the reported ownership following that transaction was 806,230 shares. The filing also reports 21,892 shares withheld to satisfy option exercise-related obligations at an average price of $8.77, and a sale of 74,108 shares on 09/15/2025 at a weighted average price of $8.7551, leaving beneficial ownership of 710,230 shares after the reported transactions.

ASP Isotopes (ASPI) announced a leadership transition. Effective October 1, 2025, founder Paul Mann became Executive Chairman and began a temporary leave from Chief Executive Officer duties for health reasons. The Board appointed Chief Operating Officer Robert Ainscow as Interim CEO (principal executive officer) in addition to his current role.

Mr. Mann will guide strategy and support senior management alongside the Board, while Mr. Ainscow will manage CEO direct reports and external communications. The company made no new employment arrangements for Robert Ainscow. The filing notes Robert is the brother of Donald Ainscow, EVP, General Counsel and Secretary, whose compensation includes a base salary of $425,000 and an initial grant of 400,000 shares vesting over four years.